VESPA
13.2.2024 15:01:32 CET | Business Wire | Press release
Vespa, supplier of the leading platform for applications that leverage AI and data online at scale, today announced it has earned recognition as a leader and forward mover in the GigaOm Sonar for Vector Databases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240213670564/en/
GigaOm Sonar Reports evaluate technology that is new, interesting, and attractive but poses intrinsic risk when it comes to enterprise adoption. These reports give you the right information at the right time to help plan your strategy. Vespa is positioned as a Leader and Forward Mover in GigaOm's latest report on vector databases. (Graphic: Business Wire)
The research cites Vespa as a platform leader “because of its widespread embedding flexibility, rapid time for updating, and hybrid search capabilities–with neural network rankings. These are critical to maximizing the ROI for vector similarity search engines.”
Andrew Brust, Analyst, GigaOm: “Interest in the vector database market is surging as industries seek advanced AI to manage vast unstructured data. Vespa is well placed in this market with strengths that include model versatility, search flexibility and real-time capabilities.”
Daniel Doro, Director of Engineering, Search, Spotify: “As a reliable and scalable solution, Vespa has been instrumental in enabling Search at Spotify. We look forward to continuing our work with the Vespa team and enabling innovation that will enhance the experience for Spotify listeners.”
Jungwon Byun, COO & Cofounder, Elicit: “Vespa is a battle-tested platform that allows us to integrate keyword and vector search seamlessly. It forms a key part of our AI research solution, guaranteeing precision and rapidity in streamlining research processes. We highly recommend Vespa for its reliability and efficiency.”
Jon Bratseth, CEO and Founder, Vespa: “We are pleased to be recognized as a leader in an emerging, highly relevant, and rapidly growing market. AI is getting significant attention for its role in solving today's data challenges found in eCommerce, digital media, financial services and other industries. Vespa enables organizations to realize this opportunity. GigaOm brings clarity to this crowded and hype laden market.”
In October 2023, Vespa was spun out from Yahoo as an independent company, although the technology has existed for over a decade. Yahoo remains a key investor with Vespa technology underpinning approximately 150 applications that are integral to Yahoo’s operations.
The GigaOm Sonar for Vector Databases can be downloaded here:
https://content.vespa.ai/gigaom-report-2024
About Vespa
Vespa is a platform for applications which leverage AI and data to deliver experiences to end users online in real time, such as search, recommendation, personalization, and retrieval-augmented generation (RAG). Vespa automatically organizes data, inference and logic to allow applications to work with any amount of data, queries, and is available both as a managed service and as open source.
About Elicit
Elicit is the first AI research assistant using language models to automate research workflows like literature review. Over 250,000 researchers in leading academic and industry labs around the world use Elicit every month to summarize papers and extract insights at scale.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240213670564/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom